Vanda Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Vanda Pharmaceuticals ha un patrimonio netto totale di $541.2M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $645.1M e $103.9M.

Informazioni chiave

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessi	n/a
Contanti	US$376.26m
Patrimonio netto	US$541.22m
Totale passività	US$103.89m
Totale attività	US$645.12m

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Vanda's Struggles Persist Despite New Drug Launches And Takeover Bids

Sep 05

Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over

Aug 08

Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest

Jun 18

Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much

Apr 05

Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Feb 15

Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash

Feb 13

Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement

Feb 10

News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts

Nov 11

One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

May 12

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $432.4M ) di VNDA superano le sue passività a breve termine ( $89.1M ).

Passività a lungo termine: Le attività a breve termine di VNDA ( $432.4M ) superano le sue passività a lungo termine ( $14.8M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: VNDA è esente da debiti.

Riduzione del debito: VNDA non ha avuto debiti negli ultimi 5 anni.

Copertura del debito: VNDA non ha debiti, pertanto non deve essere coperto dal flusso di cassa operativo.

Copertura degli interessi: VNDA non ha debiti, pertanto la copertura dei pagamenti degli interessi non è un problema.

Vanda Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Vanda Pharmaceuticals Inc. Revises Revenue Guidance for the Full Year 2024

Vanda Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 06, 2024

Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA for approximately $490 million.

FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis

Vanda's Struggles Persist Despite New Drug Launches And Takeover Bids

Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over

Vanda Pharmaceuticals Inc. Reinstates Financial Guidance for the Full Year 2024

Vanda Pharmaceuticals Inc. to Report Q2, 2024 Results on Jul 31, 2024

Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Value-Defensive Index

Future Pak, Ltd. cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., Renaissance Technologies LLC, BlackRock, Inc. (NYSE:BLK), Butler Hall Capital LLC, Shareholder Capital LLC and others.

Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA).

Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest

Cycle Pharmaceuticals Limited made a proposal to acquire Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) for approximately $490 million.

Future Pak, Ltd. cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., Renaissance Technologies LLC, BlackRock, Inc. (NYSE:BLK), Butler Hall Capital LLC, Shareholder Capital LLC and others.

Vanda Pharmaceuticals Inc. Reports Positive Results from A Second Phase III Study of Tradipitant in Motion Sickness

First quarter 2024 earnings released: US$0.072 loss per share (vs US$0.057 profit in 1Q 2023)

Price target increased by 23% to US$5.21

Vanda Pharmaceuticals Inc. to Report Q1, 2024 Results on May 08, 2024

Future Pak, Ltd. submits a proposal to acquire Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., State Street Corporation (NYSE:STT), BlackRock, Inc. (NYSE:BLK), Dimensional Fund Advisors LP and others for approximately $450 million.

Future Pak, Ltd. submits a proposal to acquire Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., State Street Corporation (NYSE:STT), BlackRock, Inc. (NYSE:BLK), Dimensional Fund Advisors LP and others for approximately $450 million.

Consensus EPS estimates fall from profit to US$0.06 loss, revenue upgraded

Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much

New minor risk - Share price stability

Vanda Pharmaceuticals' Fanapt (Iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder

Insider recently sold US$73k worth of stock

Founder notifies of intention to sell stock

Vanda Pharmaceuticals Announces FDA Update for Supplemental NDA for HETLIOZ in the Treatment of Insomnia

Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Consensus revenue estimates increase by 27%

Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash

Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia

Vanda Pharmaceuticals Inc. to Report Q4, 2023 Results on Feb 07, 2024

Vanda Pharmaceuticals Inc. Announces U.S. Food and Drug Administration Approval for VTR-297 for the Treatment of Onychomycosis

Vanda Pharmaceuticals Inc. Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S

Now 21% undervalued after recent price drop

Vanda Pharmaceuticals Inc. Announces U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis

Now 21% undervalued after recent price drop

News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts

Third quarter 2023 earnings released: EPS: US$0.002 (vs US$0.058 in 3Q 2022)

Vanda Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 08, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Vanda Pharmaceuticals Inc. to Report Q2, 2023 Results on Jul 27, 2023

Senior VP recently sold US$96k worth of stock

Senior VP notifies of intention to sell stock

Vanda Pharmaceuticals Inc Reports Results from a Phase III study of Tradipitant in Motion Sickness

One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

Vanda Pharmaceuticals Inc. Responds to the Ruling in its Hetlioz(R) Abbreviated New Drug Application Appeal

First quarter 2023 earnings released: EPS: US$0.057 (vs US$0.12 loss in 1Q 2022)

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane